Process for reducing blood pressure and blocking .beta.-adrenergic
receptor
    22.
    发明授权
    Process for reducing blood pressure and blocking .beta.-adrenergic receptor 失效
    减少血压和阻止{62-肾上腺素能受体的方法

    公开(公告)号:US4147799A

    公开(公告)日:1979-04-03

    申请号:US463833

    申请日:1974-04-24

    IPC分类号: C07D317/58 A61K31/36

    CPC分类号: C07D317/58

    摘要: Ethanolamine derivatives and their acid addition salts are prepared (1) by reacting a 1-(3,4-methylenedioxyphenyl)-2-aminoethanol compound or an .alpha.-amino-(3,4-methylenedioxy)acetophenone compound with an alkanal or an alkanone under reduction conditions, (2) by hydrogenating and/or hydrogenolyzing a 1-(3,4-methylenedioxyphenyl)-2-(N-substituted amino)-ethanol compound or an .alpha.-(N-substituted amino)-(3,4-methylenedioxy)acetophenone compound, and (3) by reacting a (3,4-methylenedioxyphenyl)-ethylene oxide compound or a 1-(3,4-methylenedioxyphenyl)-2-substituted ethanol compound with an amine. The ethanolamine derivatives and their salts show .beta.-adrenergic receptor blocking activity, and are expected to be useful in the treatment of heart disease, hypertension, myocardites and pheochromocytoma.

    摘要翻译: 通过使1-(3,4-亚甲二氧基苯基)-2-氨基乙醇化合物或α-氨基 - (3,4-亚甲二氧基)苯乙酮化合物与链烷醛或烷酮反应制备乙醇胺衍生物及其酸加成盐(1) 在还原条件下,(2)通过氢化和/或氢解1-(3,4-亚甲二氧基苯基)-2-(N-取代的氨基) - 乙醇化合物或α-(N-取代的氨基) - (3,4 - 亚甲二氧基)苯乙酮化合物,和(3)使(3,4-亚甲二氧基苯基) - 二氧化乙烯化合物或1-(3,4-亚甲二氧基苯基)-2-取代的乙醇化合物与胺反应。 乙醇胺衍生物及其盐显示β-肾上腺素能受体阻断活性,预计可用于治疗心脏病,高血压,心肌和嗜铬细胞瘤。

    Tricyclic compounds
    23.
    发明授权
    Tricyclic compounds 失效
    三环化合物

    公开(公告)号:US5478840A

    公开(公告)日:1995-12-26

    申请号:US294978

    申请日:1994-08-24

    摘要: A tricyclic compound represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen, halogen or lower alkyl; A represents cyano, carboxyl, tetrazolyl, cyano-substituted phenyl, carboxyl-substituted phenyl or tetrazolyl-substituted phenyl; V represents --(CH.sub.2).sub.m --(wherein m is an integer of 0 to 2); W represents ##STR2## (wherein R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen, halogen, lower alkyl, cycloalkyl, halogenated lower alkyl, hydroxy, lower alkoxy, amino, lower alkylamino, carboxyl or lower alkoxycarbonyl; and Q.sup.1 --Q.sup.2 --Q.sup.3 --Q.sup.4 represents N.dbd.CH--CH.dbd.CH; X.sup.1 --X.sup.2 --X.sup.3 represents CH.dbd.CH--CH.dbd.CH, S--CH.dbd.CH or CH.dbd.CH--S; Y represents a single bond, CH.sub.2, O, S, CH.sub.2 O, OCH.sub.2, CH.sub.2 S, SCH.sub.2, CH.sub.2 CH.sub.2 or CH.dbd.CH; and Z.sup.1 --Z.sup.2 represents C.dbd.CH, CH--CH.sub.2 or CH--CH(COOH)-- or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits antagonism to angiotensin II receptors.

    摘要翻译: 由下式(I)表示的三环化合物:其中R 1表示氢,卤素或低级烷基; A代表氰基,羧基,四唑基,氰基取代的苯基,羧基取代的苯基或四唑基取代的苯基; V表示 - (CH 2)m - (其中m为0〜2的整数); W表示(其中R2,R3和R4独立地表示氢,卤素,低级烷基,环烷基,卤代低级烷基,羟基,低级烷氧基,氨基,低级烷基氨基,羧基或低级烷氧基羰基;以及Q1-Q2-Q3-Q4 表示N = CH-CH = CH; X 1 -X 2 -X 3表示CH = CH-CH = CH,S-CH = CH或CH = CH-S; Y表示单键,CH 2,O,S,CH 2 O,OCH 2 ,CH2S,SCH2,CH2CH2或CH = CH; Z1-Z2表示C = CH,CH-CH2或CH-CH(COOH) - 或其药学上可接受的盐。本发明化合物显示对血管紧张素II受体的拮抗作用。